Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiculoVax chikungunya vaccine
- Development stage
- Preclinical
- Lead developer
- Auro Vaccines
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VesiculoVax™ Chikungunya Vaccine is a preclinical-stage, viral vector vaccine developed by Auro Vaccines, a subsidiary of Aurobindo Pharma USA. The vaccine utilizes the VesiculoVax™ platform, which employs attenuated, replication-competent vesiculovirus (VSV) vectors engineered to express the surface glycoproteins of the Chikungunya virus (CHIKV). By presenting these antigens in their authentic form, the vaccine stimulates the immune system to produce potent neutralizing antibodies and protective immune responses. It is specifically designed to prevent the arthralgic manifestations associated with CHIKV infection. Preclinical studies have demonstrated single-dose protection against lethal infection in mouse models, and the developer has completed safety studies including repeat-dose toxicology, neurovirulence, and biodistribution in preparation for clinical development.
- Brand names
- VesiculoVax
- Other names
- VesiculoVax ChikungunyaVSV-vectored Chikungunya vaccine
02
Targets
BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)Chikungunya virus E1 glycoprotein
Beyond the preview
Go deeper on VesiculoVax chikungunya vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiculoVax chikungunya vaccine.